Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load - a Randomized Controlled Trial

NCT05195450 is registered in ClinicalTrials.gov with Institute of Liver and Biliary Sciences, India as lead sponsor.

NCT NCT05195450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05195450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load - a Randomized Controlled Trial
Lead sponsor
Institute of Liver and Biliary Sciences, India
Phase
Not applicable
Overall status
Recruiting
Start date
February 23, 2022
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-cirrhotic, chronic hepatitis b